↓ Skip to main content

A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects

Overview of attention for article published in Journal of Cancer Research & Clinical Oncology, March 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 1,527)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
twitter
5 tweeters
facebook
1 Facebook page
video
1 video uploader

Citations

dimensions_citation
108 Dimensions

Readers on

mendeley
104 Mendeley
Title
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects
Published in
Journal of Cancer Research & Clinical Oncology, March 2009
DOI 10.1007/s00432-009-0562-z
Pubmed ID
Authors

Gary Deng, Hong Lin, Andrew Seidman, Monica Fornier, Gabriella D’Andrea, Kathleen Wesa, Simon Yeung, Susanna Cunningham-Rundles, Andrew J. Vickers, Barrie Cassileth

Abstract

Cancer patients commonly use dietary supplements to "boost immune function". A polysaccharide extract from Grifola frondosa (Maitake extract) showed immunomodulatory effects in preclinical studies and therefore the potential for clinical use. Whether oral administration in human produces measurable immunologic effects, however, is unknown.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 4%
Japan 1 <1%
France 1 <1%
Unknown 98 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 24 23%
Student > Master 19 18%
Other 12 12%
Student > Bachelor 10 10%
Student > Ph. D. Student 9 9%
Other 17 16%
Unknown 13 13%
Readers by discipline Count As %
Medicine and Dentistry 34 33%
Agricultural and Biological Sciences 19 18%
Biochemistry, Genetics and Molecular Biology 13 13%
Nursing and Health Professions 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 15 14%
Unknown 14 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2020.
All research outputs
#549,396
of 15,363,529 outputs
Outputs from Journal of Cancer Research & Clinical Oncology
#5
of 1,527 outputs
Outputs of similar age
#8,006
of 190,324 outputs
Outputs of similar age from Journal of Cancer Research & Clinical Oncology
#1
of 19 outputs
Altmetric has tracked 15,363,529 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,527 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,324 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.